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Background
Recent studies have revealed that PDE5a inhibition can
suppress both acute and chronic cardiac stress responses.
Acute modulation includes the blunting of beta-adrener-
gic stimulation, which has been observed using various
PDE5a inhibitors and across several mammalian species
including human. Chronic suppression of hypertrophy
and contractile depression from PDE5a inhibitors has
been observed in hearts subjected to sustained pressure-
overload. To elucidate mechanisms for this stress modula-
tion, we performed studies in isolated mouse myocytes
and intact hearts employing genetically engineered ani-
mals and pharmacologic modulators.
Results
In isolated myocytes, 0.1–1 μM sildenafil suppresses the
positive inotropic effect of isoproterenol (ISO, 1–10 nM).
A potential mechanism to explain this response is the
stimulation of the dual-substrate PDE – PDE2, which
when activated by cGMP increases cAMP hydrolysis. How-
ever, selective inhibition of PDE2 with BAY 60–7550 did
not alter sildenafil's suppressive effects. In contrast, inhi-
bition of cGMP-dependent kinase (cGK-1) by DT-2 or rp-
8Br-PET-cGMPs blocked the sildenafil anti-adrenergic
effects. In mice expressing skeletal as opposed to cardiac
Troponin I, the former lacking serines 23, 24 that are cGK-
1 targets, sildenafil did not exhibit anti-adrenergic effects.
TnI phosphorylation analysis suggests sildenafil enhances
this above that achieved with isoproterenol, at a likely
novel site. Since co-stimulation of cGMP by ISO is
thought mediated in part by β3AR stimulation, we studied
mice genetically lacking these receptors. Sildenafil had
negligible basal effects in these mice (as previously
reported in eNOS-/- mice, and did not suppress ISO. These
data support β3-NOS-cGMP-PKG-TnI coupled modula-
tion of adrenergic stimulation by PDE5a.
cGK-1 activation is also thought to suppress hypertrophic
stimuli. Myocyte studies have shown that cGK-1 sup-
presses calcineurin-coupled NFAT activation and cell
hypertrophy. In vivo, mice lacking GC-A show upregula-
tion of this pathway, while sildenafil enhanced cGK-1
activity resulted in suppressed pressure-overload hyper-
trophy and reduced calcineurin and NFAT stimulation.
We tested the critical role of this pathway in mice lacking
calcineurin Aβ subunit (~80% knockdown of cal-
cineurin). While such mice display ~50% of the hyper-
trophic response to aortic banding compared to littermate
controls, this hypertrophy was still fully blocked by silde-
nafil. In contrast, mice lacking the regulator of G-coupled
signalling 2 (RGS2), a negative modulator of Gαq signal-
ling, had marked acceleration of hypertrophy and dilation
to pressure-overload, and this was no ameliorated by
sildenafil co-administration.
Conclusion
These new data confirm a direct role of PDE5s inhibition
on cardiac myocyte and heart regulation, and identify key
protein targets underlying its suppression of acute adren-
ergic and chronic pressure-overload stress.
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